MR. ARNOLD MARTIN HORWITZ, PH.D.
Marriage and Family Therapists at Garnette Dr, San Luis Obispo, CA

5104795, Apr 14, 1992

Feb 14, 1990

7/480003

Lindley Blair - Los Angeles CA
Arnold Horwitz - Los Angeles CA
Raju K. Koduri - Los Angeles CA

Zoma Corporation - Berkeley CA

C12P 2102, C12N 1511

435 691

A shortened PGK promoter ranging from 165 to 404 base pairs of the Saccharomyces PGK promoter is taught. The promoter is operably linked to heterologous genes and improves the expression thereof relative to the full length PGK promoter.

6204023, Mar 20, 2001

Jun 6, 1995

8/472691

Randy R. Robinson - Mountain View CA
Alvin Y. Liu - Bellevue WA
Arnold H. Horwitz - Los Angeles CA
Marc Better - Los Angeles CA
Randolph Wall - Sherman Oaks CA
Gary L. Wilcox - Mill Creek WA

XOMA Ltd.

A61K 39395, C07K 1600, C12P 1934

435 713

The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts tansformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.

2003009, May 22, 2003

Jan 9, 2002

10/040945

Randy Robinson - Los Angeles CA, US
Alvin Liu - Oceanside CA, US
Arnold Horwitz - Los Angeles CA, US
Marc Better - Los Angeles CA, US
Randolph Wall - Sherman Oaks CA, US
Gary Wilcox - Malibu CA, US

XOMA Technology Ltd.

C12P021/02, C07H021/04, C12N005/06, C07K016/40

435/069100, 435/320100, 530/388260, 435/338000, 536/023530

The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells. The invention also relates to the secretion of chimeric antibodies and fragments thereof from yeast in functional form.

5698435, Dec 16, 1997

Jun 6, 1995

8/467140

Randy R. Robinson - Los Angeles CA
Alvin Y. Liu - Oceanside CA
Arnold H. Horwitz - Los Angeles CA
Marc Better - Los Angeles CA
Randolph Wall - Sherman Oaks CA
Gary L. Wilcox - Malibu CA

Xoma Corporation - Berkeley CA

C12N 1500, C12N 500, C12P 2106, C12P 2104

4352402

The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.

5578572, Nov 26, 1996

Jan 13, 1995

8/372783

Arnold Horwitz - Los Angeles CA
Lewis H. Lambert - Fremont CA
Roger G. Little - Benicia CA

Xoma Corporation - Berkeley CA

A61K 3816, A61K 3817

514 12

The present invention relates to methods of treating gram-positive bacterial infections by administration of a BPI protein product alone, or in combination with an antibiotic. BPI protein product alone has a bactericidal or growth inhibitory effect on selected gram-positive organisms. BPI protein product also increases the susceptibility of gram-positive organisms to antibiotics and can even reverse resistance of gram-positive organisms to antibiotic.

6013631, Jan 11, 2000

Jun 19, 1998

9/099725

Arnold Horwitz - Los Angeles CA
Stephen Fitzhugh Carroll - Walnut Creek CA
David Burke - Oakland CA

XOMA Corporation - Berkeley CA

A61K 3800, C07K 100

514 12

Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.

5023173, Jun 11, 1991

Oct 14, 1986

6/918446

Arnold Horwitz - Los Angeles CA
Changtung P. Chang - Chatsworth CA

Xoma Corporation - Berkeley CA

C12Q 102, C12N 100

435 29

The present invention relates to a method and device for the in vitro testing of potential nematicidal and nematistatic agents, comprising treatment of nematodes with test substances, followed by assessment of the ability of the treated nematodes to move through a chemattractant gradient set up on a coated solid support, said coating comprising a gellable polymeric substrate incorporating a stabilizing agent.

5770561, Jun 23, 1998

Jul 11, 1994

8/274303

Arnold Horwitz - Los Angeles CA

Xoma Corporation - Berkeley CA

A61K 3816, A61K 3814

514 8

The present invention provides methods of potentiating the gram-negative bactericidal activity of BPI protein products by means of administering LBP protein products.

6051553, Apr 18, 2000

Jun 22, 1998

9/102325

Arnold Horwitz - Los Angeles CA

Xoma Corporation - Berkeley CA

A61K 3816, A61K 3800, C07K 100

514 8

The present invention provides methods of potentiating the gram-negative bactericidal activity of BPI protein products by means of administering LBP protein products.

2005013, Jun 16, 2005

Jul 29, 2003

10/629516

Arnold Horwitz - Los Angeles CA, US
Stephen Carroll - Walnut Creek CA, US
David Burke - Oakdale CA, US

A61K038/16, C07H021/04, C12N015/74, C12N009/48

514012000, 435069300, 435320100, 435212000, 435252300, 536023700

Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.